These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11749700)

  • 1. CPT-11 may provide therapeutic efficacy for esophageal squamous cell cancer and the effects correlate with the level of DNA topoisomerase I protein.
    Nakajima Y; Miyake S; Nagai K; Kawano T; Iwai T
    Jpn J Cancer Res; 2001 Dec; 92(12):1335-41. PubMed ID: 11749700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The expressions of p21 and pRB may be good indicators for the sensitivity of esophageal squamous cell cancers to CPT-11: Cell proliferation activity correlates with the effect of CPT-11.
    Nakajima Y; Miyake S; Tanaka K; Ogiya K; Toukairin Y; Kawada K; Nishikage T; Nagai K; Kawano T
    Cancer Sci; 2004 May; 95(5):464-8. PubMed ID: 15132777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11.
    Matsumoto Y; Fujiwara T; Honjo Y; Sasaoka N; Tsuchida T; Nagao S
    J Surg Oncol; 1993 Jun; 53(2):97-103. PubMed ID: 8388965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice.
    Kim R; Hirabayashi N; Nishiyama M; Jinushi K; Toge T; Okada K
    Int J Cancer; 1992 Mar; 50(5):760-6. PubMed ID: 1312063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
    Liebes L; Potmesil M; Kim T; Pease D; Buckley M; Fry D; Cho J; Adler H; Dar K; Zeleniuch-Jacquotte A; Hochster H
    Clin Cancer Res; 1998 Mar; 4(3):545-57. PubMed ID: 9533521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions.
    Philippart P; Harper L; Chaboteaux C; Decaestecker C; Bronckart Y; Gordover L; Lesueur-Ginot L; Malonne H; Lavergne O; Bigg DC; da Costa PM; Kiss R
    Clin Cancer Res; 2000 Apr; 6(4):1557-62. PubMed ID: 10778989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p16INK4 expression is associated with the increased sensitivity of human non-small cell lung cancer cells to DNA topoisomerase I inhibitors.
    Fukuoka K; Adachi J; Nishio K; Arioka H; Kurokawa H; Fukumoto H; Ishida T; Nomoto T; Yokote H; Tomonari A; Narita N; Yokota J; Saijo N
    Jpn J Cancer Res; 1997 Oct; 88(10):1009-16. PubMed ID: 9414664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of topoisomerase I catalytic activity as determinant of drug response in human cancer cell lines.
    Voigt W; Vanhoefer U; Yin MB; Minderman H; Schmoll HJ; Rustum YM
    Anticancer Res; 1997; 17(5A):3707-11. PubMed ID: 9413228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
    Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
    Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MET increases the sensitivity of gefitinib-resistant cells to SN-38, an active metabolite of irinotecan, by up-regulating the topoisomerase I activity.
    Sakai A; Kasahara K; Ohmori T; Kimura H; Sone T; Fujimura M; Nakao S
    J Thorac Oncol; 2012 Sep; 7(9):1337-44. PubMed ID: 22722827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of topoisomerase I inhibitor in cisplatin-resistant ovarian cancer.
    Minagawa Y; Kigawa J; Itamochi H; Terakawa N
    Hum Cell; 2001 Sep; 14(3):237-43. PubMed ID: 11774743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody.
    Sugimoto Y; Tsukahara S; Oh-hara T; Isoe T; Tsuruo T
    Cancer Res; 1990 Nov; 50(21):6925-30. PubMed ID: 2170010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential expression of DNA topoisomerase I gene between CPT-11 acquired- and native-resistant human pancreatic tumor cell lines: detected by RNA/PCR-based quantitation assay.
    Takeda S; Shimazoe T; Sato K; Sugimoto Y; Tsuruo T; Kono A
    Biochem Biophys Res Commun; 1992 Apr; 184(2):618-25. PubMed ID: 1315526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11].
    Matsumoto Y; Fujiwara T; Honjo Y; Sasaoka N; Tsuchida T; Nagao S
    Noshuyo Byori; 1994; 11(1):59-64. PubMed ID: 8162152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA topoisomerase I content of a pair of human melanoma cell lines with very different radiosensitivities correlates with their in vitro sensitivities to camptothecin.
    Ng CE; Cybulski SE; Bussey AM; Aubin RA; Raaphorst GP
    Anticancer Res; 1998; 18(4C):3119-26. PubMed ID: 9713520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperthermic modulation of SN-38-induced topoisomerase I DNA cross-linking and SN-38 cytotoxicity through altered topoisomerase I activity.
    Katschinski DM; Robins HI
    Int J Cancer; 1999 Jan; 80(1):104-9. PubMed ID: 9935239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line.
    Kohara H; Tabata M; Kiura K; Ueoka H; Kawata K; Chikamori M; Aoe K; Chikamori K; Matsushita A; Harada M
    Clin Cancer Res; 2002 Jan; 8(1):287-92. PubMed ID: 11801571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated topoisomerase I activity in cervical cancer as a target for chemoradiation therapy.
    Chen BM; Chen JY; Kao M; Lin JB; Yu MH; Roffler SR
    Gynecol Oncol; 2000 Nov; 79(2):272-80. PubMed ID: 11063656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-induced down-regulation of topoisomerase I in human epidermoid cancer cells resistant to saintopin and camptothecins.
    Taniguchi K; Kohno K; Kawanami K; Wada M; Kanematsu T; Kuwano M
    Cancer Res; 1996 May; 56(10):2348-54. PubMed ID: 8625310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of drug response in camptothecin-11-resistant glioma cell lines.
    Matsumoto Y; Fujiwara T; Nagao S
    J Neurooncol; 1995; 23(1):1-8. PubMed ID: 7623066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.